Highest-materiality recent filing
Skye Bioscience enters $22M ELOC with Redmile; warrant for $5M shares
ELOC facility up to $22M for common/non-voting common stock; $2M/month cap over 3-year term, pricing at lesser of PIPE price or Market Price (floor 90% of PIPE price).
Skye Bioscience receives Nasdaq delisting notice for negative stockholders' equity
Stockholders' equity was ($497,307) as of June 30, 2026, below Nasdaq's $2.5M minimum requirement.
Skye Bioscience to acquire Redx Pharma; Redx holders to own ~46% of combined company
Skye to acquire Redx Pharma via UK scheme of arrangement; Redx valued at $125M, Skye at $14.5M.
Nasdaq approved transfer from Global to Capital Market effective June 23, 2026 due to stockholders' equity of $9.0M below $10M requirement.
Skye Bioscience stockholders approve 3x increase in authorized common shares to 300M
Charter Amendment increases authorized common shares from 100M to 300M, filed with Nevada on May 28, 2026.
Skye Bioscience receives Nasdaq delisting notice for failing minimum stockholders' equity
Stockholders' equity was $9,011,804, below Nasdaq Global Market's $10M minimum requirement.
Skye Bioscience appoints John Sharp as CFO and reprices underwater options to $0.6150
John P. Sharp appointed CFO effective March 31, 2026; services via Lohman & Associates at $25,600/month for up to 64 hours.
Skye Bioscience receives Nasdaq deficiency notice for bid price below $1.00
Received deficiency letter on March 17, 2026 for failure to maintain $1.00 minimum bid price for 30 consecutive business days.
Net loss Q4 2025: $14.4M; full year $55.9M; cash & equivalents $25.7M as of Dec 31, 2025.
Nimacimab 200mg + semaglutide 2.4mg achieved 22.3% mean weight loss at 52 weeks; no plateau observed, suggesting further efficacy potential.
Skye Bioscience licenses Halozyme's ENHANZE technology for subcutaneous nimacimab
Non-exclusive license to Halozyme's ENHANZE drug delivery tech for subcutaneous nimacimab formulation.
Nimacimab plus semaglutide achieved 29% relative increase in weight loss vs semaglutide alone at 26 weeks; clean safety profile.
Nimacimab monotherapy at 200 mg failed primary endpoint with placebo-subtracted weight loss of -1.26% (p=0.2699, mITT).
Skye Bioscience Q2 net loss $17.6M; Phase 2a top-line data due late Q3/early Q4 2025
Net loss of $17.6M for Q2 2025, vs $7.9M in Q2 2024; R&D expense rose to $14.3M from $4.1M.
Skye Bioscience Q4 net loss $9.7M; Phase 2a obesity trial top-line data accelerated to late Q3 2025
Cash $68.4M at Dec 31, 2024; projected runway through at least Q1 2027.
Skye Bioscience Q3 net loss $3.9M; cash $76.5M; nimacimab Phase 2 enrolling, interim data Q2 2025
Net loss $3.9M in Q3 2024 vs $24.9M loss in Q3 2023; decrease driven by absence of $21.2M in-process R&D acquisition expense.
Skye Bioscience appoints Puneet Arora as Chief Medical Officer, grants 225,000 stock options
Puneet S. Arora, MD, appointed CMO effective Sept 3, 2024; base salary $475k with 40% target bonus.
Skye Bioscience appoints Dr. Karen Smith to board; two directors resign effective Aug 1
Appoints Dr. Karen Smith MD, PhD, MBA, LLM to board; retainer $40k/yr plus committee fees and 40,000-share option.
Phase 2a trial of SBI-100 in 56 patients with POAG or OHT did not meet primary IOP endpoint vs placebo.
Skye Bioscience reports pro forma equity >$5M after $90M private placement
Closed private placement of 15.7M shares and 10.0M pre-funded warrants for $90M gross ($83.5M net).
Skye Bioscience raises $40M via PIPE of 4M shares at $10 each
Issued 4,000,000 shares at $10.00 per share for gross proceeds of $40,000,000.
Skye Bioscience appoints Dr. Annalisa Jenkins to board; director Dalesandro to resign Aug 1
Dr. Annalisa Jenkins appointed to board effective Feb 29, 2024, filling newly created eighth seat.
Skye Bioscience raises $46.2M, sells real estate; equity now $49M for Nasdaq compliance
Net proceeds of ~$46.2M from private placement of 11.7M shares and pre-funded warrants on Jan 31, 2024.
Skye Bioscience raises $50.25M in PIPE led by 5AM Ventures; funds obesity Phase 2 trial
Private placement of 11.8M shares at $2.305 and pre-funded warrants for 9.98M shares at $2.3049.
Skye licenses SBI-100 to Tautomer for Africa, terminates UM 8930 license, sells Canadian lab
Exclusive license to Tautomer for SBI-100 (THC prodrug) suppository in Africa for chronic pain and other indications.
Board and majority stockholders approved incentive plan amendment raising authorized shares to 1,846,883, with automatic 5% annual increases from 2024-2032.
Skye Bioscience announces 1-for-250 reverse stock split effective Sept 8, 2023
Reverse split at 1:250 reduces outstanding shares from ~3.078B to ~12.3M.
Paul Grayson appointed director with a $350,000 sign-on bonus.
Skye Bioscience acquires Bird Rock Bio in $17M financing, gains Phase 2 CB1 antibody nimacimab
Acquired Bird Rock Bio; lead asset nimacimab is a phase 2-ready peripherally-restricted CB1 inhibitor for glaucoma and CKD.
Emerald Health Sciences exercised 16,641,486 warrants for $282,905, paid by reducing Skye's debt under the Credit Agreement.
Skye Bioscience closes sale of Verdélite Sciences for $9.48M; receives $5.60M cash at closing
Sold wholly owned subsidiary Verdélite Sciences and 88k sq ft cannabis facility in St-Eustache, Quebec to C3 Souvenir Holding.
Skye Bioscience faces $4.85M jury verdict in wrongful termination case; amends Verdeilite sale terms
Jury awards Wendy Cunning $512,500 economic, $840,960 non-economic, and $3.5M punitive damages; company plans to appeal.
Skye Bioscience prepays $945K debt, extends maturity, reprices warrants to $0.017
Prepaid $944,862 of principal and interest; remaining convertible debt of $1.848M.
Skye extends EHT deal outside date to Nov 15, receives $700K loan from EHT
Third Amendment extends outside date for acquisition of Emerald Health Therapeutics to November 15, 2022, subject to possible 15-day extension.
Skye shareholders approve acquisition of Emerald Health; Phase 1 trial imminent
97% of votes cast (excluding affiliates) approved the acquisition of Emerald Health Therapeutics.
In connection with Mr. Sharp’s departure, on September 9, 2026, the Board of Directors of the Company appointed Punit Dhillon, the Company’s President and Chief Executive Officer, as the Company’s principal financial and accounting officer, effective as of September 8, 2026.
On September 8, 2026, John P. Sharp resigned as Chief Financial Officer and principal financial and accounting officer of the Company, effective as of the Effective Date.
Tu Diep has entered into a previously disclosed executive employment agreement (the “ Diep Employment Agreement ”) with the Company. In connection with the Transaction, on the date hereof, the Company entered into a separation agreement with Mr. Diep (the “ Diep Separation Agreement ”) pursuant to which Mr. Diep's last day of employment with the Company will be January 31, 2027
Punit Dhillon has entered into a previously disclosed executive employment agreement (the “ Dhillon Employment Agreement ”) with the Company. In connection with the Transaction, on the date hereof, the Company entered into a separation agreement with Mr. Dhillon (the “ Dhillon Separation Agreement ”) pursuant to which Mr. Dhillon's last day of employment with the Company will be August 31, 2027
On September 3, 2024, Skye Bioscience, Inc. (the “Company”) announced the appointment of Puneet S. Arora, MD, MS, FACE, as Chief Medical Officer, effective as of September 3, 2024 (the “Effective Date”).
On July 1, 2024, each of Keith Ward, PhD and Praveen Tyle, PhD informed the Board of their intent to resign as a member of the Board, effective August 1, 2024.
the Board approved an increase in its authorized size from eight to nine members and appointed Karen L. Smith MD, PhD, MBA, LLM to fill the vacancy created by such increase.
On July 1, 2024, each of Keith Ward, PhD and Praveen Tyle, PhD informed the Board of their intent to resign as a member of the Board, effective August 1, 2024.
Margaret Dalesandro, Ph.D. informed the Board of her intent to resign as a member of the Board, effective August 1, 2024.
appointed Annalisa Jenkins, M.B.B.S., F.R.C.P. to fill the vacancy created by such increase.
Andrew Schwab and Paul Grayson were appointed to the Board.
Andrew Schwab and Paul Grayson were appointed to the Board.
Max materiality 1.00 · Median 0.65 · Most common event other_material